Development of Novel Formulations to Enhance in Vivo Transdermal Permeation of Tocopherol by Nada Aly H., Zaghloul Abdelazim A., Hedaya Mohsen M., Khattab Ibrahim S.

Get full text

A combined multi objective model to supplier evaluation and selection and order allocation using AHP and TOPSIS by Ali Nazeri, Bohlool Ebrahimi, Reza Naderikia

“…Epsilon constraint method is applied to solve the model using a pharmaceutical company data. Technique for Order of Preference by Similarity to Ideal Solution (TOPSIS) has carried out to determine the best answer Among Pareto solutions. …”
Get full text

Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review by Lei Lu, Ying Jiang, Ravindran Jaganathan, Yanli Hao

“…Literature search was done on online databases, PubMed, Google Scholar, clinitrials.gov, and browsing through individual ophthalmology journals and leading pharmaceutical company websites.…”
Get full text

How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis by Quinn Grundy, Fiona Webster, Daniel Z Buchman, Sheryl Spithoff, Ross E G Upshur, Abhimanyu Sud, Matthew Strang

“…Within this context, this study examined how the ‘Suboxone Education Programme’, developed and delivered by a pharmaceutical company as part of a federally regulated risk management program, was presented as a solution to various kinds of risks relating to opioid use in public documents from medical institutions across Canada.Setting These documents were issued during the Canadian opioid crisis, a time when the involvement of industry in health policy was being widely questioned given industry’s role in driving the overprescribing of opioid analgesics and contributing to population-level harms.Design A critical discourse analysis of 69 documents collected between July 2020 and May 2021 referencing the Suboxone Education Program spanning 13 years (2007–2021) from medical, nursing and pharmacy institutions sourced from every Canadian province and territory. …”
Get full text

Quantitative analysis of quaternary mixtures in topical creams using cutting-edge HPLC technique: environmental impact and sigma methodology by Maha A. Alwaili, Osama A. Mahmoud, Samar M. Mahgoub, Manal A. Almalki, Hassan A. Rudayni, Ahmed A. Allam, Mustafa Ahmed Abdel-Reheim, Osama A. Mohammed, Mahmoud A. Mohamed

Get full text

Optimization and Evaluation of <i>Cannabis</i>-Based Magistral Formulations: A Path to Personalized Therapy by Bożena Grimling, Magdalena Fast, Magdalena Okoniewska, Artur Owczarek, Bożena Karolewicz

Get full text

Cleaner Production Quality Regulation Strategy of Pharmaceutical with Collusive Behavior and Patient Feedback by Junmei Rong, Lilong Zhu

“…This paper’s two innovations are as follows: first, it not only considers the collusion between pharmaceutical companies and medical service agencies, but also introduces patient feedback to study drug quality regulation strategies from a microperspective; second, this paper constructs a tripartite evolutionary game model involving cleaner production pharmaceutical companies, medical service agencies, and the governments to analyze the evolutionary stability using the Lyapunov first rule. …”
Get full text

Investigating the Impact of Supply Chain Dynamics on Financial Performance with Supply Chain Disruption Structure Approach by Ebrahim Farbod, Alireza Hamidieh, Hootan Amininia

“…The statistical sample of the present study is 217 business managers of pharmaceutical companies according to the formula for determining the sample size of Cochran, observing the success ratio in this research and considering the error coefficient of 0.05. …”
Get full text

Advances in Chemical Synthesis of Fondaparinux by Yili Ding, Chamakura V. N. S. Vara Prasad, Bingyun Wang

“…Over the last two decades, several research groups and pharmaceutical companies have been interested in finding efficient and practical methods for its synthesis. …”
Get full text

EFFECT OF WORKING CAPITAL MANAGEMENT ON FIRM’S VALUE: EVIDENCE FROM LISTED PHARMACEUTICAL FIRMS IN NIGERIA by Muhammed BELLO, Adeyemi KAMARDEEN, Shakirat Opeyemi SALAWUDEEN

“…The population of this study consists of all listed pharmaceutical companies on the floor of the Nigeria Exchange Group as at 31st December, 2021. …”
Get full text

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus by Alexander C. Martins, Beatriz G. de la Torre, Fernando Albericio

“…Health authorities are working to address this issue, while pharmaceutical companies are exploring new paths to improve the quality of these drugs. …”
Get full text

THE IDENTIFICATION AND SYSTEMATIZATION OF FINANCIAL ASSETS AND LIABILITIES, EXPOSED TO FINANCIAL RISKS, ON THE EXAMPLE OF THE PHARMACEUTICAL INDUSTRY by O. Ageeva, A. Yolkina

“…The best methods of identification of the financial assets and liabilities with highest risk concentration on the example of pharmaceutical companies have been considered. It is well known, that significant risks are subject to disclosure in financial statements of organization, because they can influence management decisions. …”
Get full text

The Canadian Multicentre MAC Treatment Study by Stephen D Shafran, The Canadian HIV Trials Network

“…A Canadian Multicentre MAC Treatment Trial was proposed in 1990 and finally implemented in late 1992 via the Canadian HIV Trials Network with the assistance of 6 pharmaceutical companies. The specific drug regimens and study design are outlined and the timetable for analysis and completion are also indicated. …”
Get full text

A Better Code for a Better Relationship by Russell Williams, Paul C Adams

Get full text

Healthcare consumers' perceptions of incentive-linked prescribing: A scoping review. by Muhammad Naveed Noor, Haider Safdar Abbasi, Nina van Der Mark, Zahida Azizullah, Janice Linton, Afifah Rahman-Shepherd, Amna Rehana Siddiqui, Mishal Sameer Khan, Rumina Hasan, Sadia Shakoor

“…In addition to strong regulatory controls, it is critical that physicians self-regulate their behaviour, and publicly disclose if they have any financial ties with pharmaceutical companies. Doing so can contribute to trust between patients and physicians, an important part of patient-focused care and a contributor to user confidence in the wider health system.…”
Get full text

Médicaments génériques : pivot de la reconstruction de l’industrie pharmaceutique by Philippe Abecassis, Nathalie Coutinet

“…While some of these regulations was designed against major pharmaceutical companies (Big Pharma), firms have often co-constructed the regulation with the intent to take advantage. …”
Get full text

Omicron: The rising fear for another wave in Malaysia by Lydia Ngiik-Shiew Law, Ke-Yan Loo, Joanna Xuan Hui Goh, Priyia Pusparajah

“…Many innocent lives were lost, and the spread of infection is still ongoing. Pharmaceutical companies raced against the time to develop vaccines, believing that it would be sufficient to control COVID-19. …”
Get full text

TRANSFORMATIONAL TRENDS AND INNOVATIVE FACTORS IN THE DEVELOPMENT OF THE WHOLESALE AND RETAIL SECTORS OF THE PHARMACEUTICAL MARKET by E. A. Bykova

“…The article gives the ratings of the leading distribution pharmaceutical companies in Russia and analyses the peculiarities of their structural changes under the influence of innovative development factors. …”
Get full text

The need for Open Labs for fostering interdisciplinarities in Modern Chemistry. Biocatalysis: a necessary tool for synthetic chemists by Martin, Juliette

“…However, enzymatic catalysis is a mature technology, and this should encourage more chemists to take further ownership and expand applications in modern chemistry.In the industrial sector, some pharmaceutical companies have been pioneers in the use and acceptance of biocatalysis for the unique properties that enzymes can deliver. …”
Get full text

How to improve psychiatric nosography in the XXI century: a phenomenologist”s viewpoint by Giovanni Stanghellini

“…Classifications of mental disorders reflect much more the minds of psychiatrists than the patients’ minds since these classifications are more focused on the interests of stakeholders (including governmental agencies, advocacy groups, medical insurance, and pharmaceutical companies) than on the experiences of patients. …”
Get full text